Decibel Therapeautics

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The firm focuses on hearing disorders, including noise-induced hearing loss, residual hearing preservation or improved sound fidelity with cochlear implants, presbycusis or age-related hearing loss, tinnitus, a persistent ringing in the ears, and genetic hearing loss. It also offers drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. The company was founded by Kevin Paul Starr, M. Charles Liberman, Gabriel Corfas, Ulrich Müller, and Albert Edge in October 2015 and is headquartered in Boston, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.

The IND for DB-OTO provides clearance for the Company to initiate a pediatric Phase 1/2 clinical trial in the U.S. in children and infants, and is part of an international regulatory strategy for clinical development

Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. McLaughlin to its Board of Directors.

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY.

Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to provide durable restoration of hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency.

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September.

Decibel Therapeutics to Participate in Upcoming Investor Conferences

- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer -

Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update

AcelRx Pharmaceuticals

Yatsen Holding

Penny stocks to watch before the end of the week. The post Top Penny Stocks Today?

Top Penny Stocks Today? 3 You Might Want To Watch Before Next Week

Decibel Therapeutics Inc (NASDAQ: DBTX) reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020 to protect against hearing loss in cancer patients receiving cisplatin chemotherapy.  The interim analysis showed that 88% of.

Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study

- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear –

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET.

Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. E.T.

Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program –

Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held virtually and in Washington D.C. May 15-19, 2022.

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss -

Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:00 p.m. ET.

Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability data -

Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline

BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held virtually February 5–9, 2022.

Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The fireside chat will be available for on-demand viewing starting Monday, January 10, 2022 at 7:00 am ET.

Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointments of Alison Finger, MBA and Saraswathy (“Sara”) Nochur, Ph.D. to its Board of Directors.

Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Regeneron has extended the research term of its collaboration with the Company to discover and develop gene therapies for hearing loss. The research term will be extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10 million in Q4 of 2022.

Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss

- Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss –

Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays Gene Editing & Gene Therapy Summit on Monday, November 15, 2021. Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at 3:30 pm ET and in a panel discussion titled “Addressing Development Challenges and the Regulatory Hurdles” at 4:45 pm ET.

Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 10:30 am ET.

Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that findings from a study of noise-related inner ear damage conducted in collaboration with the University of Maryland School of Medicine (UMSOM) and the Karolinska Institute (KI) have been published in Cell Reports .

Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage

The FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to Decibel Therapeutics Inc (NASDAQ: DBTX) lead gene therapy product candidate, DB-OTO, for otoferlin-related congenital hearing loss. The Company looks forward to initiating a Phase 1/2 trial of DB-OTO in pediatric patients in 2022.

News for Decibel Therapeautics Stock (DBTX)